Still strug­gling to get an EUA, No­vavax paints ear­ly rosy pic­ture of com­bo Covid-19/flu vac­cine

As its Covid-19 vac­cine ap­pli­ca­tion founders at the FDA, No­vavax at­tempt­ed to ex­cite in­vestors Wednes­day with its ex­per­i­men­tal com­bo Covid/flu shot. But the da­ta re­main ear­ly, and com­ments from the FDA re­port­ed­ly paint a tough road to au­tho­riza­tion.

The biotech re­vealed the first re­sults from its Phase I/II study look­ing at the two-pronged vac­cine, say­ing the ob­served im­mune re­spons­es were sim­i­lar to those pro­duced by each of its stand­alone shots. As such, No­vavax says it plans to launch a “Phase II con­fir­ma­tion tri­al” by the end of the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER